NICM
NKTR icon

Neo Ivy Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Neo Ivy Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,439
Closed -$463K – 454
2026
Q1 		$463K Buy
+6,439
New +$367K 0.12% 208
2022
Q2 		– Sell
-272
Closed -$22K – 545
2022
Q1 		$22K Buy
272
+229
+533% +$33.9K 0.02% 424
2021
Q4 		$9K Sell
43
-25
-37% -$5.42K 0.01% 389
2021
Q3 		$24K Buy
+68
New +$16.4K 0.03% 382
2021
Q1 		– Sell
-309
Closed -$79K – 584
2020
Q4 		$79K Buy
+309
New +$79.8K 0.09% 272
2020
Q3 		– Sell
-68
Closed -$24K – 565
2020
Q2 		$24K Sell
68
-89
-57% -$27.8K 0.03% 382
2020
Q1 		$42K Buy
+157
New +$48.6K 0.07% 330
2019
Q1 		– Sell
-1,274
Closed -$628K – 369
2018
Q4 		$628K Buy
+1,274
New +$769K 0.49% 77

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neo Ivy Capital Management's NKTR Position: Q2 2026 in Review

Neo Ivy Capital Management sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 6,439 shares — an estimated $463K sold.

Neo Ivy Capital Management first reported a position in NKTR in Q4 2018 and held it in 8 quarters. The position peaked at $628K in Q4 2018. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Neo Ivy Capital Management reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Neo Ivy Capital Management sold 6,439 Nektar Therapeutics shares in Q2 2026, an estimated $463K.
  • Neo Ivy Capital Management first reported a position in Nektar Therapeutics in Q4 2018 and held it in 8 quarters.
  • Neo Ivy Capital Management's Nektar Therapeutics position peaked at $628K in Q4 2018.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Neo Ivy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.